CATX

Perspective Therapeutics, Inc.

CATX · CIK 728387 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20172024
Net Income−$79M
20172024
Operating CF−$18M
20172024
Free Cash Flow−$73M
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue——$0.0B$0.0B$0.0B$0.0B$0.0B—
Cost of Revenue——$0.0B$0.0B$0.0B$0.0B$0.0B—
Gross Profit—$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-1.23$-0.17$-0.01—————
EPS (Diluted)$-1.23———————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.3B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Current Assets$0.2B$0.0B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.1B$0.0B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.3B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B—
Investing Cash Flow$-0.2B$0.0B$-0.0B$-0.0B$-0.0B$0.0B$0.0B—
Capital Expenditures$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.3B$0.0B$0.0B$0.1B$0.0B$0.0B$0.0B—
← Companies